Octapharma has announced that it will be presenting two scientific symposia during the 2012 world congress of the World Federation of Haemophilia (WFH).
The company will attend the event in Paris later this month in order to discuss the latest developments in the treatment of haemophilia A and von Willebrand disease, with renowned experts in the field to lead the debate.
During the presentations, evidence-based data will be showcased that highlights knowledge in the field of haemophilia A and current findings from ongoing studies in patients with FVIII inhibitors and previously untreated patients.
Additionally, updates will be given on key aspects of the diagnosis and treatment of von Willebrand disease, including data from clinical trials and surgical procedures, as well as issues pertaining to paediatric treatment and individual pharmacokinetics.
According to Octapharma's most recent annual report, the company generated 732 million euros (582.9 million pounds) in net sales during 2011, which was two percent above its figure from the year before.See all the latest jobs in Pharmaceutical